Accelerate your Aptamer discovery using cutting-edge technologies.
From generation to in-lab validation, with an 80% success rate for nanomolar binding affinity
APTAMERS
The Next-Gen Therapeutics Molecules
Aptamers are revolutionizing precision medicine and transforming drug delivery, ushering in a new era of highly targeted and scalable therapeutics.
-
Aptamers are engineered, single-stranded oligonucleotides that fold into precise 3D structures to target and inhibit proteins, making them effective therapeutics.
- Aptamers can block disease-related interactions, carry therapeutic cargo and assemble into multi-component drug systems.
-
The power of aptamers lies in their chemical precision—they're fully synthetic, highly scalable, and easily fine-tuned for maximum stability and effectiveness.
AI-Powered Aptamer Discovery to Drug the undruggable
Mimicking Antibody Drugs for Any Protein Target
Our platform enables rapid design of nucleic acids and interactions with target proteins
Identify targets
Identify promising drug targets by exploring all possible relationships among biological entities in a comprehensive map.
Screen virtually
Our platform screens up to trillions of novel nucleic acid protein interactions in silico to discover potential drug candidates with desired properties
Optimize lead
The most promising compounds are further optimized in vitro using chemically modifications to improve pharmacokinetic properties.
Cutting-Edge Biotechnology Solutions
IN VITRO LAB VALIDATION
In vitro lab validation of aptamers involves the evaluation of their binding affinity, specificity and functionality under controlled laboratory conditions. Understanding the molecular interactions of drug candidates is crucial for successful development. Our dedicated team of biophysicists and structural biologists use spectroscopy, anisotropy and surface plasmon resonance (SPR) to investigate the molecular properties and binding kinetics of aptamer target complexes to support drug optimisation and selection. This process includes techniques such as enzyme-linked aptamer assays (ELAA) and fluorescence-based binding studies to confirm target interaction.
IN SILICO ANALYSIS
Our approach helps to rationalise the design and selection of development candidates, saving time and resources.
We use proprietary pipelines, databases and AI technologies to model the generated aptamers and predict properties such as binding affinity and folding behaviour.
Our experienced team uses advanced molecular modelling, virtual screening and structure-based drug design to identify promising lead candidates and predict target interactions.
APTAMERS GENERATION
Leveraging our extensive library of well-characterised aptamers, we can rapidly develop highly specific aptamers tailored to the target molecules of interest. Our advanced computational methods based on artificial intelligence (AI) enable us to develop and optimise novel aptamers with increased binding affinity, stability and specificity. By integrating AI-powered predictive modelling with our experimental validation processes, we can streamline the discovery of aptamers, shortening development time while improving overall efficacy. This innovative approach enables us to develop powerful aptamers for a variety of applications, including therapeutics, diagnostics and targeted drug delivery.
Discover Our Advantages
Cutting-edge Technology
We utilize state-of-the-art equipment and innovative methods to drive advancements in biotechnology research and development.
Expert Team
Our team of skilled scientists and researchers are dedicated to delivering high-quality results and pushing the boundaries of biotechnological possibilities.
Tailored Solutions
We offer customizable biotechnology solutions tailored to meet the unique needs and requirements of each client, ensuring optimal outcomes and satisfaction.
Validate Faster and Cheaper
Improved Logistic
Leading Biotech Innovators
With over 20 years in biotechnology research and development, ScienTek's team brings unparalleled expertise. We have successfully tackled complex challenges in genomics, bioinformatics, and molecular biology, pushing the boundaries of scientific discovery.
